Rebetol and Pulmonary oedema - a phase IV clinical study of FDA data

Summary:

Pulmonary oedema is reported as a side effect among people who take Rebetol (ribavirin), especially for people who are male, 50-59 old, have been taking the drug for 1 - 6 months also take Peg-Intron, and have Hepatitis c.

The phase IV clinical study analyzes which people have Pulmonary oedema when taking Rebetol. It is created by eHealthMe based on reports of 25,907 people who have side effects when taking Rebetol from the FDA, and is updated regularly.

What is Rebetol?

Rebetol has active ingredients of ribavirin. eHealthMe is studying from 25,932 Rebetol users. Check the latest studies of Rebetol.

What is Pulmonary oedema?

Pulmonary oedema (fluid accumulation in the lungs) is found to be associated with 1,848 drugs and 1,966 conditions by eHealthMe. Check the latest studies of Pulmonary oedema.

On Jul, 13, 2026

25,907 people reported to have side effects when taking Rebetol.
Among them, 81 people (0.31%) have Pulmonary oedema.

Among these 81 people:

How long have people been on Rebetol when they have Pulmonary oedema? *

What is the gender of people who have Pulmonary oedema when taking Rebetol? *

female: 24.36 %
male: 75.64 %

What is the age of people who have Pulmonary oedema when taking Rebetol? *

What are other drugs people take besides Rebetol? *

What are other side effects people have besides Pulmonary oedema? *

Nausea And Vomiting: 19 people, 23.46%
Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 18 people, 22.22%
Acute Kidney Failure: 17 people, 20.99%
Ards (Acute Respiratory Distress Syndrome) (sudden failure of the respiratory (breathing) system): 17 people, 20.99%
Fever: 16 people, 19.75%
Hepatic Failure (liver failure): 14 people, 17.28%
Pneumonia: 14 people, 17.28%
Headache (pain in head): 14 people, 17.28%
Thrombocytopenia (decrease of platelets in blood): 14 people, 17.28%
Respiratory Distress (difficulty in breathing): 12 people, 14.81%

What are the existing conditions these people have? *

Hepatitis C: 68 people, 83.95%
Insomnia (sleeplessness): 2 people, 2.47%
High Blood Pressure: 2 people, 2.47%
Hepatic Cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue): 2 people, 2.47%
Back Pain: 2 people, 2.47%
Gout (uric acid crystals building up in the body): 1 person, 1.23%
Chronic Hepatitis (long lasting inflammation of liver): 1 person, 1.23%

* Approximation only. Some reports may have incomplete information.

Do you take Rebetol and have Pulmonary oedema?

- Check whether Pulmonary oedema is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rebetol:

Rebetol (25,932 reports)

Pulmonary oedema treatments and more:

Pulmonary oedema (53,624 reports)

Browse all side effects of Rebetol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pulmonary oedema:

Pulmonary oedema (1,848 drugs)

Browse all the conditions that are associated with Pulmonary oedema:

Pulmonary oedema (1,966 conditions)

Related publications that referenced our studies

Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .
Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on ribavirin (the active ingredients of Rebetol) and Rebetol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.